Eric Easom - 19 Mar 2026 Form 4 Insider Report for AN2 Therapeutics, Inc. (ANTX)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: ANTX
Reported as of: 19 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Mar 2026, 19:00:23 UTC
Prior SEC filing: 23 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Lucy Day, Attorney-in-Fact for Eric Easom

Key filing fact

Eric Easom filed Form 4 for AN2 Therapeutics, Inc. (ANTX) on 23 Mar 2026.

Key facts

This page summarizes Eric Easom's Form 4 filing for AN2 Therapeutics, Inc. (ANTX).
6 reported transactions and 6 derivative rows are listed below.
Accepted by SEC: 23 Mar 2026, 19:00.

Change

Previous filing in this sequence was filed on 23 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001914503 Primary reporting owner

Easom Eric

Relationship: Chief Executive Officer, Director
Address: C/O AN2 THERAPEUTICS, INC., 1300 EL CAMINO REAL, SUITE 100, MENLO PARK
Signature: /s/ Lucy Day, Attorney-in-Fact for Eric Easom
Signature date: 23 Mar 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ANTX transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +249,999
Change %
Price
Shares after: 249,999
Date: 19 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 249,999
Exercise price: $3.91
Footnotes: F1, F2, F3

ANTX transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -249,999
Change %: -100%
Price
Shares after: 0
Date: 19 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 249,999
Exercise price: $6.60
Footnotes: F2, F3

ANTX transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +225,000
Change %
Price
Shares after: 225,000
Date: 19 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 225,000
Exercise price: $3.91
Footnotes: F1, F3, F4

ANTX transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -225,000
Change %: -100%
Price
Shares after: 0
Date: 19 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 225,000
Exercise price: $17.28
Footnotes: F3, F4

ANTX transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +267,650
Change %
Price
Shares after: 267,650
Date: 19 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 267,650
Exercise price: $3.91
Footnotes: F1, F3, F5

ANTX transaction Derivative

Stock Option (right to buy)

Disposed to Issuer

Transaction value
Shares: -267,650
Change %: -100%
Price
Shares after: 0
Date: 19 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 267,650
Exercise price: $11.99
Footnotes: F3, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "Premium End Date" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The "Premium End Date" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability.

Footnote F2

The option is fully vested.

Footnote F3

On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged.

Footnote F4

The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary measured from March 25, 2022, subject to the Reporting Person's continuous service through each applicable vesting date.

Footnote F5

The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary measured from January 1, 2023, subject to the Reporting Person's continuous service through each applicable vesting date.